Banque Pictet & Cie SA Increases Stock Position in Humana Inc. (NYSE:HUM)

Banque Pictet & Cie SA increased its holdings in Humana Inc. (NYSE:HUM - Free Report) by 8.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,695 shares of the insurance provider's stock after acquiring an additional 3,154 shares during the quarter. Banque Pictet & Cie SA's holdings in Humana were worth $10,768,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of HUM. Linden Thomas Advisory Services LLC boosted its stake in Humana by 9.4% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 1,801 shares of the insurance provider's stock worth $477,000 after purchasing an additional 154 shares in the last quarter. Greenleaf Trust boosted its holdings in shares of Humana by 12.9% in the first quarter. Greenleaf Trust now owns 2,322 shares of the insurance provider's stock worth $614,000 after buying an additional 266 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in Humana by 2.6% during the first quarter. DekaBank Deutsche Girozentrale now owns 57,151 shares of the insurance provider's stock valued at $14,996,000 after purchasing an additional 1,449 shares in the last quarter. M&T Bank Corp boosted its position in shares of Humana by 9.8% in the first quarter. M&T Bank Corp now owns 9,265 shares of the insurance provider's stock worth $2,451,000 after purchasing an additional 828 shares during the period. Finally, Crossmark Global Holdings Inc. lifted its position in shares of Humana by 3.3% in the first quarter. Crossmark Global Holdings Inc. now owns 9,364 shares of the insurance provider's stock valued at $2,478,000 after acquiring an additional 296 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Down 0.8%

Shares of NYSE:HUM traded down $1.80 during trading hours on Friday, hitting $230.38. 1,077,538 shares of the company's stock traded hands, compared to its average volume of 1,811,368. The firm has a market capitalization of $27.80 billion, a P/E ratio of 16.29, a price-to-earnings-growth ratio of 1.79 and a beta of 0.44. The business has a fifty day moving average price of $238.33 and a 200-day moving average price of $258.48. Humana Inc. has a 1 year low of $212.45 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The firm had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. During the same period last year, the company earned $7.23 EPS. Humana's quarterly revenue was up 8.4% compared to the same quarter last year. Equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.54%. Humana's payout ratio is 25.04%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on HUM shares. Mizuho lifted their target price on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Bank of America reduced their price objective on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research report on Tuesday, June 17th. Barclays set a $268.00 target price on shares of Humana and gave the stock an "equal weight" rating in a report on Thursday, June 12th. Oppenheimer raised their target price on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Finally, Guggenheim assumed coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target on the stock. Sixteen equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $280.76.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.